• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Elisabeth M. Paietta, PhD, Defines Minimum Residual Disease (MRD) and Discusses the Current Challenges of MRD Implementation

Article

Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.

Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.

This video was taken on Sunday, December 9, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.

Related Videos
Ivo Carre, PhD, senior business analyst, Lifescience Dynamics
AHA 2025 recap layered on photo of Bourbon Street in New Orleans | Image credit: SeanPavonePhoto - stock.adobe.com
Screenshot of an interview with Stephen Nicholls, MBBS, PhD
Screenshot of an interview with Roy Mathew, MD
Screenshot of an interview with Vallerie McLaughlin, MD
Oncology experts at PCOC
Susan Cantrell, CEO of AMCP
Michael Hassett, MD, MPH
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.